## Edgar Filing: McVicar William K. - Form 4

McVicar William K. Form 4 June 18, 2018							
		URITIES AND EXCHANG /ashington, D.C. 20549	E COMMISSION	OMB APPROVAL OMB 3235-0287 Number:			
Subject to Section 16. Form 4 or		ANGES IN BENEFICIAL O SECURITIES	WNERSHIP OF	Kumber.Expires:January 31, 2005Estimated average burden hours per response0.5			
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							
(Print or Type Responses)							
1. Name and Address of Rep McVicar William K.	Symbo	uer Name <b>and</b> Ticker or Trading bl Pharma, Inc. [FLKS]	5. Relationship of Reporting Person(s) to Issuer				
(Last) (First) C/O FLEX PHARMA,	(Middle) 3. Data (Month	3. Date of Earliest Transaction       (Check all applicable)         3. Date of Earliest Transaction					
BOYLSTON STREET (Street)		mendment, Date Original	Presid	President and CEO ual or Joint/Group Filing(Check			
BOSTON, MA 02199	Filed(1	Month/Day/Year)	Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State)	(Zip) T	able I - Non-Derivative Securities		or Beneficially Owned			
1.Title of Security (Instr. 3)2. Transaction (Month/Day/ (Instr. 3)	Date 2A. Deemed (ear) Execution Date, if any (Month/Day/Year)	Code Disposed of (D)	SecuritiesForBeneficially(EOwned(E)Following(InReportedTransaction(s)(Instr. 3 and 4)	Ownership7. Nature oform: DirectIndirectO) or IndirectBeneficial)Ownershipnstr. 4)(Instr. 4)			
Reminder: Report on a separa	te line for each class of so	ecurities beneficially owned directly Persons who re information cor		ire not (9-02)			
			ently valid OMB cont				

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date 3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year) Execution Da	te, if Transa	ctionDerivative	Expiration Date	Underlying Securities
Security	or Exercise	any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

## Edgar Filing: McVicar William K. - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A Disposed o (Instr. 3, 4, 5)	f (D)				
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 1.35	06/14/2018		А		359,696		(1)	06/14/2028	Common Stock	359,696

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
1	Director	10% Owner	Officer	Other			
McVicar William K. C/O FLEX PHARMA, INC. 800 BOYLSTON STREET BOSTON, MA 02199	Х		President and CEO				
Signatures							
/s/ John McCabe, Attorney-in-Fact	(	06/18/2018					
**Signature of Reporting Person		Date					

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The stock option will vest in 48 successive equal monthly installments measured from June 14, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.